108 related articles for article (PubMed ID: 16007222)
1. Myeloid maturation block by AML1-MTG16 is associated with Csf1r epigenetic downregulation.
Rossetti S; Van Unen L; Touw IP; Hoogeveen AT; Sacchi N
Oncogene; 2005 Aug; 24(34):5325-32. PubMed ID: 16007222
[TBL] [Abstract][Full Text] [Related]
2. A distinct epigenetic signature at targets of a leukemia protein.
Rossetti S; Hoogeveen AT; Liang P; Stanciu C; van der Spek P; Sacchi N
BMC Genomics; 2007 Feb; 8():38. PubMed ID: 17266773
[TBL] [Abstract][Full Text] [Related]
3. AML1-ETO decreases ETO-2 (MTG16) interactions with nuclear receptor corepressor, an effect that impairs granulocyte differentiation.
Ibañez V; Sharma A; Buonamici S; Verma A; Kalakonda S; Wang J; Kadkol S; Saunthararajah Y
Cancer Res; 2004 Jul; 64(13):4547-54. PubMed ID: 15231665
[TBL] [Abstract][Full Text] [Related]
4. Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation.
Kitabayashi I; Yokoyama A; Shimizu K; Ohki M
EMBO J; 1998 Jun; 17(11):2994-3004. PubMed ID: 9606182
[TBL] [Abstract][Full Text] [Related]
5. AML1/ETO-induced survivin expression inhibits transcriptional regulation of myeloid differentiation.
Balkhi MY; Christopeit M; Chen Y; Geletu M; Behre G
Exp Hematol; 2008 Nov; 36(11):1449-60. PubMed ID: 18687517
[TBL] [Abstract][Full Text] [Related]
6. [Construction and tumorigenic study on a novel fusion gene AML1-MTG16].
Wang Y; Lu S; Kong H; Wang L; Yuan W; Sun Y; Jing Y; Lu Z; Wang Z; Wang Z
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Aug; 19(4):271-5. PubMed ID: 12170460
[TBL] [Abstract][Full Text] [Related]
7. The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells.
Senyuk V; Chakraborty S; Mikhail FM; Zhao R; Chi Y; Nucifora G
Oncogene; 2002 May; 21(20):3232-40. PubMed ID: 12082639
[TBL] [Abstract][Full Text] [Related]
8. Subnuclear targeting of Runx1 is required for synergistic activation of the myeloid specific M-CSF receptor promoter by PU.1.
Li X; Vradii D; Gutierrez S; Lian JB; van Wijnen AJ; Stein JL; Stein GS; Javed A
J Cell Biochem; 2005 Nov; 96(4):795-809. PubMed ID: 16149049
[TBL] [Abstract][Full Text] [Related]
9. Forced expression of AML1-AMP19, a fusion transcript generated from a radiation-associated t(19;21) leukemia, blocks myeloid differentiation.
Ramsey H; Christopherson K; Hromas R
Leuk Res; 2004 Aug; 28(8):863-8. PubMed ID: 15203284
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins.
Moldenhauer A; Frank RC; Pinilla-Ibarz J; Holland G; Boccuni P; Scheinberg DA; Salama A; Seeger K; Moore MA; Nimer SD
J Leukoc Biol; 2004 Sep; 76(3):623-33. PubMed ID: 15197237
[TBL] [Abstract][Full Text] [Related]
11. E2a/Pbx1 oncogene inhibits terminal differentiation but not myeloid potential of pro-T cells.
Bourette RP; Grasset MF; Mouchiroud G
Oncogene; 2007 Jan; 26(2):234-47. PubMed ID: 16819510
[TBL] [Abstract][Full Text] [Related]
12. Expression and regulation of the evi-1 gene in the human factor-dependent leukemia cell line, UCSD/AML1.
Oval J; Smedsrud M; Taetle R
Leukemia; 1992 May; 6(5):446-51. PubMed ID: 1593910
[TBL] [Abstract][Full Text] [Related]
13. The Runx1 transcription factor controls CSF-1-dependent and -independent growth and survival of macrophages.
Himes SR; Cronau S; Mulford C; Hume DA
Oncogene; 2005 Aug; 24(34):5278-86. PubMed ID: 16007221
[TBL] [Abstract][Full Text] [Related]
14. Decreased intranuclear mobility of acute myeloid leukemia 1-containing fusion proteins is accompanied by reduced mobility and compartmentalization of core binding factor beta.
Qiu J; Wong J; Tweardy DJ; Dong S
Oncogene; 2006 Jun; 25(28):3982-93. PubMed ID: 16474840
[TBL] [Abstract][Full Text] [Related]
15. MicroRNAs 17-5p-20a-106a control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation.
Fontana L; Pelosi E; Greco P; Racanicchi S; Testa U; Liuzzi F; Croce CM; Brunetti E; Grignani F; Peschle C
Nat Cell Biol; 2007 Jul; 9(7):775-87. PubMed ID: 17589498
[TBL] [Abstract][Full Text] [Related]
16. The chimeric genes AML1/MDS1 and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1/MDS1 has tumor-promoter properties.
Zent CS; Mathieu C; Claxton DF; Zhang DE; Tenen DG; Rowley JD; Nucifora G
Proc Natl Acad Sci U S A; 1996 Feb; 93(3):1044-8. PubMed ID: 8577711
[TBL] [Abstract][Full Text] [Related]
17. ELA2 is regulated by hematopoietic transcription factors, but not repressed by AML1-ETO.
Lausen J; Liu S; Fliegauf M; Lübbert M; Werner MH
Oncogene; 2006 Mar; 25(9):1349-57. PubMed ID: 16247445
[TBL] [Abstract][Full Text] [Related]
18. Erythroid inhibition by the leukemic fusion AML1-ETO is associated with impaired acetylation of the major erythroid transcription factor GATA-1.
Choi Y; Elagib KE; Delehanty LL; Goldfarb AN
Cancer Res; 2006 Mar; 66(6):2990-6. PubMed ID: 16540647
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein.
Fazi F; Racanicchi S; Zardo G; Starnes LM; Mancini M; Travaglini L; Diverio D; Ammatuna E; Cimino G; Lo-Coco F; Grignani F; Nervi C
Cancer Cell; 2007 Nov; 12(5):457-66. PubMed ID: 17996649
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional and epigenetic regulation of the GM-CSF promoter by RUNX1.
Oakford PC; James SR; Qadi A; West AC; Ray SN; Bert AG; Cockerill PN; Holloway AF
Leuk Res; 2010 Sep; 34(9):1203-13. PubMed ID: 20439113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
